Notes
Conflict of Interest
Cheon JH has received personal fees from Celltrion Inc., Eisai Korea, Ferring Korea, IQVIA, Ferring, Janssen Korea, Shire Korea, and Takeda Korea. Paridaens K is an employee of Ferring Pharmaceuticals. Al Awadhi S has participated in advisory board for Ferring. Begun J has received honoraria, research grants or consulting fees from AbbVie, Janssen, Takeda, Pfizer, Ferring, Bristol-Myers Squibb, Gilead, Tillotts, Sandoz, Chiesi, Celltrion, Microba, and Antara. Fullarton JR is an employee of Violicom Medical Limited that has received funding from Ferring for work on various projects. Louis E has received research grants from Janssen, Pfizer, and Takeda; educational grants from AbbVie, Janssen, MSD, and Takeda; speaker fees from AbbVie, Falk, Ferring, Hospira, Janssen, MSD, Pfizer, and Takeda; participated in advisory boards for AbbVie, Celgene, Ferring, Hospira, Janssen, MSD, Pfizer, Takeda, Galapagos, Gilead, Arena, Elli Lilly; consultant for AbbVie. Magro F has served as speaker and received honoraria from AbbVie, Biogen, Bristol-Myers Squibb, Falk, Ferring, Hospira, Janssen, Laboratórios Vitoria, Pfizer, Lilly, Merck Sharp & Dohme, Sandoz, Takeda, UCB, and Vifor. Marquez JR has received sponsorship as speaker from AbbVie, Biopas, Biotoscana, Farma, Ferring, Janssen, and Takeda. Moschen AR is receiving research support from AbbVie and Takeda under the framework of the Christian Doppler Research Society; has received further consultation fees and/or speaker honoraria from AbbVie, Merck Sharp & Dohme, Takeda, Janssen-Cilag, Amgen, Sandoz, Nestlé, Ferring, Falk, and Pfizer. Narula N has received grants, advisory board fees, or speakers bureau honoraria from Janssen, AbbVie, Takeda, Pfizer, Merck, Sandoz, Novartis, and Ferring. Rydzewska G has received grants/research support or speakers fee from AbbVie, Alfasigma, Astellas, Ferring, Janssen, Pfizer, Pharmabest, Recordati, Sanprobi, Sandoz, Vitama, and Takeda. Dignass AU has received fees for participation in clinical trials, review activities, such as data monitoring boards, statistical analysis, end point committees from Falk, AbbVie, Janssen, Gilead and Pfizer; consultancy fees from AbbVie, MSD, Ferring, Roche/Genentech, Takeda, Vifor, Pharmacosmos, Boehringer-Ingelheim, Gilead, Galapagos, Falk, Janssen, Pfizer, Sandoz/Hexal, BMS/Celgene, Tillotts, Amgen and Fresenius Kabi; payment from lectures including service on speakers bureaus from Falk Foundation, Ferring, MSD, AbbVie, Vifor, Janssen, Pfizer, Tillotts, Takeda, Gilead/Galapagos; payment for development of educational presentations from Tillotts and Ferring. Travis SPL has received grants/research support from: AbbVie, Buhlmann, Celgene, IOIBD, Janssen, Lilly, Pfizer, Takeda, UCB, Vifor, and Norman Collisson Foundation; Consulting fees from: Abacus, AbbVie, Actial, ai4gi, Alcimed, Allergan, Amgen, Aptel, Arena, Asahi, Aspen, Astellas, Atlantic, AstraZeneca, Barco, Biocare, Biogen, BLPharma, Boehringer-Ingelheim, BMS, Buhlmann, Calcico, Celgene, Cellerix, Cerimon, ChemoCentryx, Chiesi, Cisbio, Comcast, Coronado, Cosmo, Ducentis, Dynavax, Elan, Enterome, Equillium, Falk, Ferring, FPRT Bio, Galapagos, Genentech/Roche, Genzyme, Gilead, Glenmark, Grunenthal, GSK, GW Pharmaceuticals, Immunocore, Immunometabolism, Indigo, Janssen, Lexicon, Lilly, Medarex, Medtrix, Merck, Merrimack, Millenium, Neovacs, Novartis, Novo Nordisk, NPS-Nycomed, Ocera, Optima, Origin, Otsuka, Palau, Pentax, Pfizer, Pharmaventure, Phillips, P&G, Pronota, Proximagen, Resolute, Robarts, Sandoz, Santarus, Satisfai, Sensyne, Shire, Sigmoid Pharma, Sorriso, Souffinez, Synedria, Synthon, Takeda, Theravance, Tigenix, Tillotts, TopiVert, Trino Therapeutics with Wellcome Trust, TxCell, UCB Pharma, Vertex, VHsquared, Vifor, Warner Chilcott, and Zeria; Speaker fees from: AbbVie, Amgen, Biogen, Falk; Ferring, Janssen, Pfizer, Shire, Takeda, UCB; he holds no stocks or share options.
Cheon JH and Travis SPL are editorial board members of the journal but were not involved in the peer reviewer selection, evaluation, or decision process of this article. No other potential conflicts of interest relevant to this article were reported.
Author Contribution
Conception and design of study: Travis SPL, Paridaens K, Fullarton JR. Acquisition of data: Cheon JH, Travis SPL, Al Awadhi S, Begun J, Louis E, Magro F, Marquez JR, Moschen AR, Narula N, Rydzewska G, Dignass AU. Statistical analysis: Fullarton JR. Interpretation of results and approval of the final version of the manuscript: all authors.
Supplementary Material
REFERENCES
Table 1.
Rank | ≤ 10 years’ experience as consultant | Loadingb | > 10 years’ experience as consultant | Loadingb |
---|---|---|---|---|
1 | Consideration of the patient’s priorities | 1.44176 | Spending time with patients to educate them about their disease | 1.74546 |
2 | Discussion of other treatment options including dose optimization if the patient is complaining | 1.35474 | Empower the patient to comply with treatment by education about taking control of their lifelong disease | 1.71184 |
3 | If the diagnosis is mainly proctitis, then the focus should be on topical therapy | 1.28097 | Educating patients that after 8 years of remission under self-management they may need to think about getting checked for colon cancer | 1.62321 |
4 | Evaluation of patient-reported outcomes | 1.27074 | Communicating with the patient and fully discussing the therapeutic options | 1.54253 |
5 | Education of the patient that adherence to treatment contributes to staying in remission | 1.26619 | Informing the patient about different treatment options in case of relapse | 1.40111 |
6 | Empower the patient to comply with treatment by education about taking control of their lifelong disease | 1.24751 | Consideration of good quality of life as the ultimate goal | 1.39107 |
7 | Whether the patient has more than 2 relapses within a year | 1.24744 | Consideration of the patient’s priorities | 1.38313 |
8 | Consideration of how to increase adherence to treatment by discussing different treatment options | 1.22443 | Engaging the patient in their management through education and understanding their disease | 1.36954 |
9 | Keeping on 5-ASA for maintenance | 1.20303 | Re-assuring the patients who may be worried or anxious or feel stigmatized about a diagnosis of UC | 1.31937 |
10 | Communicating with the patient and fully discussing the therapeutic options | 1.18654 | Discussion of other treatment options including dose optimization if the patient is complaining | 1.29268 |
11 | Engaging the patient in their management through education and understanding their disease | 1.15988 | Evaluation of patient-reported outcomes | 1.27312 |
12 | Consideration of whether steroids were used to treat the last flare and for how long | 1.15284 | Educating the patient on when to seek hospital help or simply communicate with nurses or physicians | 1.21947 |
13 | Knowledge of prior steroid therapy in terms of tolerability and (duration of) response in this patient | 1.14426 | Education of the patient that adherence to treatment contributes to staying in remission | 1.18309 |
14 | Educating patients that after 8 years of remission under self-management they may need to think about getting checked for colon cancer | 1.11688 | Evaluate disease activity e.g., frequency of bowel movement, blood in stool, abdominal pain to guide treatment choices | 1.15397 |
15 | Consideration of the patient’s history of adherence to treatment | 1.11328 | Whether the patient has more than 2 relapses within a year | 1.15004 |
16 | Establishing contingency plans with the patient in case of relapse | 1.10797 | Goals of therapy may change with time | 1.12751 |
17 | Ensuring that the patient is still in full remission | 1.09711 | Patient's history of prior treatment (s) and response (s) | 1.10814 |
18 | Optimizing 5-ASA dose post-flare to avoid future relapses | 1.08640 | Let patients know that your interests align with their interests, and they should continue to comply with medical recommendations | 1.09215 |
19 | Challenges in persuading the patient to use rectal therapy, especially if disease is confined to the rectum | 1.05239 | Usefulness of “top and tail” (oral and rectal) therapy for proctitis and distal colitis | 1.07814 |
20 | After a second or third course of steroids whether 5-ASA may not be maintaining the patient well enough | 1.02339 | Giving the patient a personalized structured plan of how to manage their medication in remission | 1.04708 |
21 | Spending time with patients to educate them about their disease | 1.01786 | Understanding how the previous flare was treated | 1.00879 |
22 | Checking compliance especially with rectal treatment | 0.99982 | Establishing contingency plans with the patient in case of relapse | 0.99874 |
23 | Understanding how the previous flare was treated | 0.99545 | Consideration that patient focus on functional symptoms post-flare may lead them to consider that treatment is not working | 0.99764 |
24 | Evaluate disease activity e.g., frequency of bowel movement, blood in stool, abdominal pain to guide treatment choices | 0.99456 | Educating patients on increasing rectal therapy when there is blood in the stool | 0.99214 |
25 | Consideration of the severity of disease at initial diagnosis | 0.94804 | Consideration of whether steroids were used to treat the last flare and for how long | 0.99196 |
a Principal component analysis that encompassed the majority of the data variance for each experience group. Shaded factors are those related more to patient communication, education and feedback versus more clinically related factors.